ArticleBritish journal of clinical pharmacology2025
Lamivudine and tenofovir pharmacokinetic variability in people with HIV in Papua New Guinea.
Article in British journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lamivudine and tenofovir pharmacokinetic variability in people with HIV in Papua New Guinea.British journal of clinical pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsDemographics and kidney function contribute to variability in lamivudine and tenofovir drug concentrations. The aim was to assess, for the first time, the pharmacokinetic variability of lamivudine and tenofovir in Papua New Guinean (PNG) HIV/AIDS patients.
methodsFor 121 PNG HIV/AIDS patients receiving combination antiretroviral therapy (300 mg lamivudine, 300 mg tenofovir disoproxil fumarate, 600 mg efavirenz, single tablet once daily), age, body weight, sex and serum creatinine concentrations data were recorded. Plasma lamivudine and tenofovir concentrations were simultaneously quantified by liquid chromatography-tandem mass spectrometry. Univariate and multivariate linear regression analyses were performed to assess the association of demographic covariates and kidney function with plasma lamivudine and tenofovir concentrations.
resultsExcluding 9 patients with plasma lamivudine and tenofovir concentrations below the lower limits of quantitation, median (range) plasma lamivudine and tenofovir concentrations were 188 (15.5-1099) and 64.4 (15-251) ng/mL, respectively, and were highly correlated (Spearman ρ = 0.75, P < 2.2 × 10
conclusionA specific, precise and accurate method was validated for the simultaneous quantitation of tenofovir and lamivudine in human plasma and was successfully applied to PNG HIV/AIDS patients to reveal large and correlated interpatient variability in tenofovir and lamivudine exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.